23 July 2020
Gilead Sciences today announced the appointment of Ric Morgan as the new Head of Legal and Compliance ANZ for Gilead Sciences in Australia and New Zealand (ANZ).
Mr Morgan joins Gilead Sciences ANZ with more than 17 years of experience as a lawyer and leader in pharmaceutical, market access, regulatory, litigation and IP. Prior to joining Gilead Sciences ANZ he was at respected leading local law firm Allens Linklaters, where he held various roles of increasing responsibility since 2002, most recently as Special Counsel and Deputy Leader of the Healthcare Sector Practice Team.
Mr Morgan said about his new role “The healthcare sector has always been where my passion lies and it’s exciting to be joining Gilead Sciences during this unprecedented time. Having already had the pleasure of working closely with the team I’m pleased to join Gilead and support the company’s important work in bringing vital treatments to patients.”
Jaime McCoy, General Manager, Gilead Sciences Australia New Zealand, said “We are thrilled to have Ric join the Gilead team. Ric has provided excellent external counsel to us over the years and is a pragmatic and strategic business partner. He is a pleasure to work with and I know he will be a huge asset in our work to ensure patients can access Gilead’s diverse range of medicines and treatments.”
Mr Morgan takes over the role of Head of Legal and Compliance ANZ from Lena Moran-Adams who was recently promoted to the role of Head of Legal and Compliance for Gilead’s Intercontinental Region to be based in the UK. In this new role Ms Moran-Adams will be responsible for legal strategy and execution in emerging and distributor markets throughout Asia, Middle East, Russia and Latin America.
Ms Moran-Adams commented “The legal team at Gilead are very excited to formally bring Mr Morgan’s expertise and insights in-house. I know there is a lot we can all learn from him and from his many years of experience in the field.”
Mr Morgan will be based in the company’s Australian head office in Melbourne and will lead Gilead’s in-house Legal & Business Conduct team.
In Australia, Gilead therapy areas include HIV , Liver Disease, Haematology Oncology and Inflammation. Gilead’s 30-year heritage was built in virology, firstly in HIV, then viral hepatitis and now emerging viruses, most recently in COVID-19, blood cancer and inflammatory disease. Gilead played a critical role working with the Australian government to secure reimbursed universal access to Hepatitis C direct-acting antiviral (DAA) therapies for the estimated 180,000 Australians living with the disease. Gilead also worked with the government and the HIV community to secure reimbursed access to all Australians for HIV prevention therapy (PrEP, or Pre-Exposure Prophylaxis) in 2018, supporting Australia’s progress toward the UNAIDS’ 90-90-90 HIV treatment target.
